[go: up one dir, main page]

WO2003040369A3 - Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines - Google Patents

Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines Download PDF

Info

Publication number
WO2003040369A3
WO2003040369A3 PCT/IB2002/004219 IB0204219W WO03040369A3 WO 2003040369 A3 WO2003040369 A3 WO 2003040369A3 IB 0204219 W IB0204219 W IB 0204219W WO 03040369 A3 WO03040369 A3 WO 03040369A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumoral
reversion
apoptosis
suppression
medicines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/004219
Other languages
French (fr)
Other versions
WO2003040369A2 (en
Inventor
Adam Telerman
Robert Amson
Marius Tuijnder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Engines Laboratories Ste
Original Assignee
Molecular Engines Laboratories Ste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Engines Laboratories Ste filed Critical Molecular Engines Laboratories Ste
Publication of WO2003040369A2 publication Critical patent/WO2003040369A2/en
Anticipated expiration legal-status Critical
Publication of WO2003040369A3 publication Critical patent/WO2003040369A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns in particular novel sequences involved in the molecular pathways of tumoral suppression, tumoral reversion, apoptosis and/or viral resistance. The invention also concerns the use of said sequences for treatment against cancer, viral diseases, neurodegenerative diseases and for diagnostic purposes as well as for implementing methods for screening compounds to be tested. The invention further concerns methods for detecting and/or assaying the inventive sequences or their expression products in a biological sample.
PCT/IB2002/004219 2001-09-17 2002-09-17 Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines Ceased WO2003040369A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/11981 2001-09-17
FR0111981 2001-09-17

Publications (2)

Publication Number Publication Date
WO2003040369A2 WO2003040369A2 (en) 2003-05-15
WO2003040369A3 true WO2003040369A3 (en) 2004-07-29

Family

ID=8867345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004219 Ceased WO2003040369A2 (en) 2001-09-17 2002-09-17 Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines

Country Status (1)

Country Link
WO (1) WO2003040369A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087372A2 (en) * 2002-04-12 2003-10-23 Molecular Engines Laboratories Growth factor derived from hepatome and the use of the same
US8163482B2 (en) 2006-02-23 2012-04-24 Nicholas Katsanis BBS10 related diagnostic methods for Bardet-Biedl syndrome
WO2013142187A1 (en) 2012-03-19 2013-09-26 Malaysian Palm Oil Board Gene controlling shell phenotype in palm
MY156871A (en) * 2013-07-18 2016-04-07 Malaysian Palm Oil Board Detection methods for oil palm shell alleles
NO344051B1 (en) * 2017-05-04 2019-08-26 Patogen As Novel virus in Fish and Method for detection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017434A2 (en) * 1995-11-09 1997-05-15 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis
WO1997022695A2 (en) * 1995-12-20 1997-06-26 Fondation Jean Dausset-Ceph Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer
WO2000008147A1 (en) * 1998-08-05 2000-02-17 Molecular Engines Laboratories Genes involved in the molecular paths for tumour suppression and /or resistance to viruses
WO2001051670A2 (en) * 2000-01-07 2001-07-19 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001057182A2 (en) * 2000-01-31 2001-08-09 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001059063A2 (en) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017434A2 (en) * 1995-11-09 1997-05-15 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis
WO1997022695A2 (en) * 1995-12-20 1997-06-26 Fondation Jean Dausset-Ceph Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer
WO2000008147A1 (en) * 1998-08-05 2000-02-17 Molecular Engines Laboratories Genes involved in the molecular paths for tumour suppression and /or resistance to viruses
WO2001051670A2 (en) * 2000-01-07 2001-07-19 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001057182A2 (en) * 2000-01-31 2001-08-09 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001059063A2 (en) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRENNER SYDNEY ET AL: "Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays.", NATURE BIOTECHNOLOGY, vol. 18, no. 6, June 2000 (2000-06-01), pages 630 - 634, XP002199492, ISSN: 1087-0156 *
DATABASE GSN [online] 23 January 2002 (2002-01-23), XP002237861, Database accession no. ABA16909 *
DATABASE GSN [online] 7 November 2001 (2001-11-07), XP002237857, Database accession no. AAK83051 *
DATABASE GSN [online] 7 November 2001 (2001-11-07), XP002237858, Database accession no. AAK87567 *
DATABASE GSN [online] 7 November 2001 (2001-11-07), XP002237859, Database accession no. AAK83993 *
DATABASE GSN [online] 7 November 2001 (2001-11-07), XP002237860, Database accession no. AAK82571 *

Also Published As

Publication number Publication date
WO2003040369A2 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
WO2010015607A3 (en) Method of evaluating oral cancer risk in human
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
TW200736253A (en) Pyridopyrazine derivatives and their use
WO2004089951A8 (en) Imidazopyridine derivatives having an affinity for melanocortin receptors
WO2007141280A3 (en) Proteins
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
EP1570081A4 (en) Amplified genes involved in cancer
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
WO2003040369A3 (en) Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
WO2007058968A3 (en) Gene expression profiles and methods of use
WO2002064731A3 (en) Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
EP2209000A3 (en) Detection, monitoring and treatment of cancer
WO2003025176A8 (en) Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
WO2003025175A3 (en) Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
WO2004113574A3 (en) Methods for disease screening
WO2004040312A3 (en) Method for ngf assay for in vitro diagnosis of breast cancer and therapeutic use
WO2003004526A3 (en) Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines
WO2008090177A3 (en) Diagnosis of prostate cancer
WO2003025177A3 (en) Sequences involved in phenomena of tumour suppression, tumour reversion, adoptosis and/or resistance to viruses and the use thereof as medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP